A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study-Reference-Cited by-同舟云学术

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Published:2024-05 Issue:3 Volume:25 Page:266-273.e5
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Garon Edward B.,Cho Byoung Chul,Luft Alexander,Alatorre-Alexander Jorge,Geater Sarayut Lucien,Trukhin Dmytro,Kim Sang-We,Ursol Grygorii,Hussein Maen,Lim Farah Louise,Yang Cheng-Ta,Araujo Luiz Henrique,Saito Haruhiro,Reinmuth Niels,Kohlmann Milena,Lowery Caitlin,Mann Helen,Peters Solange,Mok Tony S.,Johnson Melissa L.

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Reference18 articles.

1. Biomarkers of response to PD-1 pathway blockade;Li;Br J Cancer,2022

2. Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon?;Chocarro de Erauso;Front Pharmacol,2020

3. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1);Kowanetz;Proc Nat Acad Sci USA,2018

4. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer;Waterhouse;Lung Cancer,2021

5. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: a real-world study of a large Chinese cohort;Jin;J Thorac Dis,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC;Journal of Thoracic Oncology;2024-08